S'abonner

Colorectal cancer incidence trends in younger versus older adults: an analysis of population-based cancer registry data - 03/01/25

Doi : 10.1016/S1470-2045(24)00600-4 
Hyuna Sung, PhD a, , Rebecca L Siegel, MPH a, Mathieu Laversanne, MSc b, Chenxi Jiang, MPH a, Eileen Morgan, PhD b, Mariam Zahwe, PhD b, Yin Cao, ScD c, d, e, Freddie Bray, PhD b, Ahmedin Jemal, PhD a
a Surveillance and Health Equity Science, American Cancer Society, Atlanta, GA, USA 
b Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France 
c Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St Louis, MO, USA 
d Division of Gastroenterology, John T Milliken Department of Medicine, Washington University School of Medicine, St Louis, MO, USA 
e Alvin J Siteman Cancer Center, St Louis, MO, USA 

* Correspondence to: Dr Hyuna Sung, American Cancer Society, Atlanta, GA, USA American Cancer Society Atlanta GA USA

Summary

Background

Previous studies have shown that colorectal cancer incidence is increasing among younger adults (aged <50 years) in multiple high-income western countries in contrast with stabilising or decreasing trends in incidence in older adults (aged ≥50 years). This study aimed to investigate contemporary colorectal cancer incidence trends in younger adults versus older adults.

Methods

Colorectal cancer incidence data, including year of diagnosis, sex, and 5-year age group for 50 countries and territories, were extracted from the WHO–International Agency for Research on Cancer Cancer Incidence in Five Continents Plus database. The Human Development Index 2022 was retrieved from the United Nations Development Programme and grouped into very high (>0·80), high (0·70–0·79), medium (0·55–0·69), and low (<0·55) categories. Age-standardised incidence rates (ASR) per 100 000 person-years of early-onset (diagnosed between ages 25 to 49 years) and late-onset (diagnosed between ages 50 to 74 years) colorectal cancer (ICD 10th revision, C18–20), diagnosed between 1943–2003 and 2015–17, were calculated using the direct method and Segi–Doll world standard population). The primary study objective was to examine contemporary colorectal cancer incidence trends in younger adults versus older adults using data until 2017 from 50 countries and territories. Temporal trends were visualised and quantified with joinpoint regression, stratified by age at diagnosis (25–49 years or 50–74 years). Average annual percentage changes (AAPC) were estimated.

Findings

In the most recent 5 years (2013–17 for all countries analysed, except for Japan [2011–15], Spain [2012–16], and Costa Rica [2012–16]), the incidence rate of early-onset colorectal cancer was highest in Australia (ASR 16·5 [95% CI 16·1–16·9]), the USA (Puerto Rico; 15·2 [14·2–16·2]), New Zealand (14·8 [14·0–15·6]), the USA (14·8 [14·7–14·9]), and South Korea (14·3 [14·0–14·5]) and lowest in Uganda (4·4 [3·6–5·2]) and India (3·5 [3·3–3·7]). The highest incidence rates among older adults were found in the Netherlands (168·4 [166·9–170·0]) and Denmark (158·3 [155·8–160·9]) and the lowest were in Uganda (45·9 [38·5–51·4]) and India (23·5 [22·8–24·3]). In terms of AAPC, in the most recent 10 years, incidence rates of early-onset colorectal cancer were stable in 23 countries, but increased in 27 countries with the greatest annual increases in New Zealand (AAPC 3·97% [95% CI 2·44–5·52]), Chile (3·96% [1·26–6·74]), Puerto Rico (3·81% [2·68–4·96]), and England (3·59% [3·12–4·06]). 14 of the 27 countries and territories showed either stable (Argentina, France, Ireland, Norway, and Puerto Rico) or decreasing (Australia, Canada, Germany, Israel, New Zealand, Slovenia, England, Scotland, and the USA) trends in older adults. For the 13 countries with increasing trends in both age groups, the average annual percentage increase in younger compared to older adults was higher in Chile, Japan, Sweden, the Netherlands, Croatia, and Finland; lower in Thailand, France (Martinique), Denmark, and Costa Rica; and similar in Türkiye, Ecuador, and Belarus. The rise in early-onset colorectal cancer was faster among men than women in Chile, Puerto Rico, Argentina, Ecuador, Thailand, Sweden, Israel, and Croatia, whereas faster increase among women compared to men was in England, Norway, Australia, Türkiye, Costa Rica, and Scotland.

Interpretation

Early-onset colorectal cancer incidence rates are rising in 27 of 50 countries and territories examined, with the rise either exclusive to early-onset disease or faster than the increase in older adults in 20 of the 27 countries. The findings underscore the need for intensified efforts to identify factors driving these trends and increase awareness to help facilitate early detection.

Funding

Intramural Research Program of the American Cancer Society, Cancer Grand Challenges, and National Institutes of Health.

Le texte complet de cet article est disponible en PDF.

Plan


© 2025  The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 26 - N° 1

P. 51-63 - janvier 2025 Retour au numéro
Article précédent Article précédent
  • Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trial
  • Icro Meattini, Maria Carmen De Santis, Luca Visani, Marta Scorsetti, Alessandra Fozza, Bruno Meduri, Fiorenza De Rose, Elisabetta Bonzano, Agnese Prisco, Valeria Masiello, Eliana La Rocca, Ruggero Spoto, Carlotta Becherini, Gladys Blandino, Luca Moscetti, Riccardo Ray Colciago, Riccardo A Audisio, Etienne Brain, Saverio Caini, Marije Hamaker, Orit Kaidar-Person, Matteo Lambertini, Livia Marrazzo, Calogero Saieva, Tanja Spanic, Vratislav Strnad, Sally Wheelwright, Philip M P Poortmans, Lorenzo Livi, EUROPA Trial Investigators, Icro Meattini, Maria Carmen De Santis, Luca Visani, Marta Scorsetti, Alessandra Fozza, Bruno Meduri, Fiorenza De Rose, Elisabetta Bonzano, Agnese Prisco, Valeria Masiello, Eliana La Rocca, Ruggero Spoto, Carlotta Becherini, Gladys Blandino, Luca Moscetti, Riccardo Ray Colciago, Riccardo A Audisio, Etienne Brain, Saverio Caini, Marije Hamaker, Orit Kaidar Person, Matteo Lambertini, Livia Marrazzo, Tanja Spanic, Vratislav Strnad, Sally Wheelwright, Philip M P Poortmans, Lorenzo Livi, Francesca Martella, Lorenzo Vinante, Sara Ramella, Marco Gatti, Sara Pedretti, Patrizia Vici, Nadia G Di Muzio, Alice Pastorino, Maria Cristina Leonardi, Ivica Ratosa, Jure Verbancic
| Article suivant Article suivant
  • Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study
  • Toni K Choueiri, Jaime R Merchan, Robert Figlin, David F McDermott, Edward Arrowsmith, M Dror Michaelson, Scott S Tykodi, Elisabeth I Heath, David R Spigel, Anishka D’Souza, Laurent Kassalow, Rodolfo F Perini, Donna Vickery, Todd M Bauer

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.